Hyaluronidase Power Injection Market Share

North American Market Statistics

North America industry is set to dominate majority revenue share of 30% by 2037. This is due to the increasing number of experimental procedures that present an in-vitro assessment of the biological attainability of hyaluronidase and the appearance of key players producing these products in the region. According to The American Society of Plastic Surgeons (ASPS), the globe's largest plastic surgery company, symbolizing 92 percent of all board-certified plastic surgeons in the United States data released in 2022, there were 26.2 million surgical and minimally invasive cosmetic and reconstructive techniques experimented as well as executed in the United States in 2022. More particularly, there has been a 19% surge in cosmetic surgery techniques since 2019. Moreover, the high adoption of progressed therapy choices and an acknowledgeable number of dermatology clinics advocating such therapies contribute to immense market expansion across North America.

APAC Market Analysis

Asia Pacific hyaluronidase power injection market is projected to expand at the quickest CAGR during the forecast period and is set to hold the position of second largest shareholder with almost 26% profit share. This growth is wheeled as a result of medical tourism for dermatology therapies and dermatological device applications in different countries of the region. In line with the Korea Health Industry Development Institute, the number of medical tourists exploring South Korea increased eightfold in ten years—from 60,000 in 2011 to almost half a million in 2021. Overseas patients now make up almost half of all plastic surgeries executed in South Korea. In addition, the presence of a significant number of suppliers together with the emergence of technologies in South Korea is further anticipated to drive the market expansion.